Top

Published in:

01-06-2016 | Review Article

Parasites and immunotherapy: with or against?

Authors: Hossein Yousofi Darani, Morteza Yousefi, Marzieh Safari, Rasool Jafari

Published in: Journal of Parasitic Diseases | Issue 2/2016

Abstract

Immunotherapy is a sort of therapy in which antibody or antigen administrates to the patient in order to treat or reduce the severity of complications of disease. This kind of treatment practiced in a wide variety of diseases including infectious diseases, autoimmune disorders, cancers and allergy. Successful and unsuccessful immunotherapeutic strategies have been practiced in variety of parasitic infections. On the other hand parasites or parasite antigens have also been considered for immunotherapy against other diseases such as cancer, asthma and multiple sclerosis. In this paper immunotherapy against common parasitic infections, and also immunotherapy of cancer, asthma and multiple sclerosis with parasites or parasite antigens have been reviewed.

Adorini L, Sinigaglia F (1997) Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today 18:209–211. doi:10.1016/S0167-5699(97)01031-1 PubMedCrossRef

Aranzamendi C, de Bruin A, Kuiper R, Boog CJ, van Eden W, Rutten V, Pinelli E (2013) Protection against allergic airway inflammation during the chronic and acute phases of Trichinella spiralis infection. Clini Exp Allergy 43:103–115. doi:10.1111/cea.12042 CrossRef

Araujo MI, Campos RA, Cardoso LS, Oliveira SC, Carvalho EM (2010) Immunomodulation of the allergic inflammatory response: new developments. Inflamm Allergy Drug Targets 9:73–82. doi:10.2174/187152810791292836 PubMedCrossRef

Aref N, Shirzad H, Yousefi M, Darani HY (2012) Effect of different hydatid cyst molecules on hela and vero cell lines growth in vitro. J Immunodefic Disor 2:1. doi:10.4172/2324-853X.1000105

Arrowood MJ, Sterling CR, Healey MC (1991) Immunofluorescent microscopical visualization of trails left by gliding Cryptosporidium parvum sporozoites. J Parasitol 77:315–317PubMedCrossRef

Badaro R, Lobo I, Munõs A, Netto EM, Modabber F, Campos-Neto A et al (2006) Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 194:1151–1159. doi:10.1086/507708

Barral-Netto M, da Silva JS, Barral A, Reed S (1995) Up-regulation of T helper 2 and down-regulation of T helper 1 cytokines during murine retrovirus-induced immunodeficiency syndrome enhances susceptibility of a resistant mouse strain to Leishmania amazonensis. Am J Pathol 146:635–642PubMedPubMedCentral

Berriel E et al (2013) Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. ScientificWorldJournal 2013:230176. doi:10.1155/2013/230176 PubMedPubMedCentralCrossRef

Bjorneby JM, Hunsaker BD, Riggs MW, Perryman LE (1991) Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum. Infect Immun 59:1172–1176PubMedPubMedCentral

Bonilla-Musoles F (1984) Immunotherapy in vaginal trichomoniasis–therapeutic and prophylactic effects of the vaccine SolcoTrichovac [Abstract]. Gynakol Rundsch 24(Suppl 3):63–69PubMedCrossRef

Bonnin A, Dubremetz JF, Camerlynck P (1993) A new antigen of Cryptosporidium parvum micronemes possessing epitopes cross-reactive with macrogamete granules. Parasitol Res 79:8–14PubMedCrossRef

Borja-Cabrera GP et al (2004) Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22:2234–2243. doi:10.1016/j.vaccine.2003.11.039 PubMedCrossRef

Boulter-Bitzer JI, Lee H, Trevors JT (2007) Molecular targets for detection and immunotherapy in Cryptosporidium parvum. Biotechnol Adv 25:13–44. doi:10.1016/j.biotechadv.2006.08.003 PubMedCrossRef

Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA (2000) Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 22:73–79PubMedCrossRef

Camargo EP (2009) Perspectives of vaccination in Chagas disease revisited. Mem Inst Oswaldo Cruz 104(Suppl 1):275–280PubMedCrossRef

Carrero Rangel JA, Horacio Borges R, Convit García J, Avilan Rovira J, Lima HD (2011) Immunotherapy of cutaneous leishmaniasis: factors that influence their effectiveness [Abstract]. Boletín de Malariología y Salud Ambiental 51:25–33

Casadevall A (1996) Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 2:200–208. doi:10.3201/eid0203.960306 PubMedPubMedCentralCrossRef

Casadevall A, Scharff MD (1994) Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 38:1695–1702PubMedPubMedCentralCrossRef

Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Diseases 21:150–161CrossRef

Cevallos AM, Zhang X, Waldor MK, Jaison S, Zhou X, Tzipori S et al (2000) Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. Infect Immun 68:4108–4116

Chamond N, Coatnoan N, Minoprio P (2002) Immunotherapy of Trypanosoma cruzi infections. Curr Drug Targets Immune Endocr Metabol Disord 2:247–254PubMedCrossRef

Cheever AW et al (1994) Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis [Abstract]. J Immunol 153:753–759PubMed

Chen L et al (2011) Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS ONE 6:e24407. doi:10.1371/journal.pone.0024407 PubMedPubMedCentralCrossRef

Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Investig 104:777–785. doi:10.1172/jci7325 PubMedPubMedCentralCrossRef

Convit J, Rondon A, Ulrich M, Bloom B, Castellanos P, Pinardi M, Castes M, Garcia L et al (1987) Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1:401–405. doi:10.1016/S0140-6736(87)90116-4

Convit J, Castellanos PL, Ulrich M, Castes M, Rondon A, Pinardi ME et al (1989) Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 160:104–115. doi:10.1093/infdis/160.1.104 PubMedCrossRef

Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M et al (2003) Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 97:469–472PubMedCrossRef

Cooper PJ (2004) Intestinal worms and human allergy. Parasite Immunol 26:455–467. doi:10.1111/j.0141-9838.2004.00728.x PubMedCrossRef

Correale J (1950) Farez MF (2013) Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway. J Immunol 191:3827–3837. doi:10.4049/jimmunol.1301110 CrossRef

Correale J (2014) Helminth/Parasite treatment of multiple sclerosis. Curr Treat Options Neurology 16:296. doi:10.1007/s11940-014-0296-3 PubMedCrossRef

Crabb JH (1998) Antibody-based immunotherapy of cryptosporidiosis. Adv Parasitol 40:121–149PubMedCrossRef

Darani HY, Yousefi M (2012) Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy. Future Oncol 8:1529–1535. doi:10.2217/fon.12.155 PubMedCrossRef

Darani HY, Shirzad H, Mansoori F, Zabardast N, Mahmoodzadeh M (2009) Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model. Korean J Parasitol 47:175–177. doi:10.3347/kjp.2009.47.2.175 PubMedPubMedCentralCrossRef

de Souza W, de Carvalho TM, Barrias ES (2010) Review on Trypanosoma cruzi: host Cell Interaction. International J Cell Biol. doi:10.1155/2010/295394

de Vries JE (1998) The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 102:165–169PubMedCrossRef

Duthie MS, Wleklinski-Lee M, Smith S, Nakayama T, Taniguchi M, Kahn SJ (2002) During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun 70:36–48PubMedPubMedCentralCrossRef

Falcone FH, Pritchard DI (2005) Parasite role reversal: worms on trial. Trends Parasitol 21:157–160. doi:10.1016/j.pt.2005.02.002 PubMedCrossRef

Falcone FH, Loukas A, Quinnell RJ, Pritchard DI (2004) The innate allergenicity of helminth parasites. Clin Rev Allergy Immunol 26:61–72. doi:10.1385/criai:26:1:61 PubMedCrossRef

Fayer R (2009) General Biology. In: Fayer R, Xiao L (eds) Cryptosporidium and cryptosporidiosis, 2nd edn. CRC Press/Taylor & Francis Group, New York, pp 1–35

Fayer R, Ellis W (1993) Paromomycin is effective as prophylaxis for cryptosporidiosis in dairy calves [Abstract]. J Parasitol 79:771–774PubMedCrossRef

Fayer R, Guidry A, Blagburn BL (1990) Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice. Infect Immun 58:2962–2965PubMedPubMedCentral

Fayer R, Morgan U, Upton SJ (2000) Epidemiology of Cryptosporidium: transmission, detection and identification. Int J Parasitol 30:1305–1322PubMedCrossRef

Figueiredo CA, Cooper P, Barreto M, Alcantara-Neves NM, Barnes K (2012) Conference scene: parasites to treat immune-mediated diseases? Immunotherapy 4:573–575. doi:10.2217/imt.12.44 PubMedCrossRef

Fleming JO (2013) Helminth therapy and multiple sclerosis. Int J Parasitol 43:259–274. doi:10.1016/j.ijpara.2012.10.025 PubMedCrossRef

Freeman GJ, Sharpe AH (2012) A new therapeutic strategy for malaria: targeting T cell exhaustion. Nature Immunol 13:113–115. doi:10.1038/ni.2211 CrossRef

Galvan-Ramirez Mde L, Troyo R, Roman S, Calvillo-Sanchez C, Bernal-Redondo R (2012) A systematic review and meta-analysis of Toxoplasma gondii infection among the Mexican population. Parasites Vectors 5:271. doi:10.1186/1756-3305-5-271 PubMedCrossRef

Genaro O, de Toledo VP, da Costa CA, Hermeto MV, Afonso LC, Mayrink W (1996) Vaccine for prophylaxis and immunotherapy. Brazil Clin Dermatol 14:503–512PubMedCrossRef

Gombosova A, Demes P, Valent M (1986) Immunotherapeutic effect of the lactobacillus vaccine, Solco Trichovac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis. Genitourin Med 62:107–110PubMedPubMedCentral

Grogl M, Thomason TN, Franke ED (1992) Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 47:117–126PubMed

Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M (2006) Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3:e162. doi:10.1371/journal.pmed.0030162 PubMedPubMedCentralCrossRef

Holaday BJ, Sadick MD, Wang ZE, Reiner SL, Heinzel FP, Parslow TG (1950) Locksley RM (1991) Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines [Abstract]. J Immunol 147:1653–1658

Hsueh EC, Morton DL (2003) Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 13:401–407. doi:10.1016/j.semcancer.2003.09.003 PubMedCrossRef

Hyde JE (2007) Drug-resistant malaria—an insight. FEBS J 274:4688–4698. doi:10.1111/j.1742-4658.2007.05999.x PubMedPubMedCentralCrossRef

Jafari R, Maghsood AH, Fallah M (2013) Prevalence of Cryptosporidium Infection among livestock and humans in contact with livestock in Hamadan District, Iran, 2012. J Res Health Sci 13:86–89

Jafari R, Maghsood AH, Safari M, Latifi M, Fallah M. Comparison of fecal antigen detection using enzyme linked immunosorbent assay (ELISA) with auramine-phenol staining method for diagnosis of human cryptosporidiosis. Jundishapur J Microbiol (in press)

Jafari R, Sadaghian M, Safari M (2012) Seroprevalence of Toxoplasma gondii Infection and Related Risk Factors in Tabriz City, Iran, 2008. J Res Health Sci 12:119–121PubMed

Jafari R, Fallah M, Yousofi Darani H, Yousefi HA, Mohaghegh MA, Latifi M, Sadaghian M, Maghsood AH (2014a) Prevalence of intestinal parasitic infections among rural inhabitants of Hamadan city, Iran, 2012. Avicenna J Clin Microbiol Infect 1:e21445

Jafari R, Gharibi Z, Fallah M (2014b) The Prevalence of Cryptosporidium infection among renal transplanted patients in Hamadan city West of Iran. Avecinna J Clin Microbiol Infect 1:e19570

Jenkins MC, Fayer R (1995) Cloning and expression of cDNA encoding an antigenic Cryptosporidium parvum protein. Mol Biochem Parasitol 71:149–152PubMedCrossRef

Jenkins MC, O’Brien C, Trout J, Guidry A, Fayer R (1999a) Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. Vaccine 17:2453–2460PubMedCrossRef

Jenkins MC, Trout J, Murphy C, Harp JA, Higgins J, Wergin W, Fayer R (1999b) Cloning and expression of a DNA sequence encoding a 41-kilodalton Cryptosporidium parvum oocyst wall protein. Clin Diagn Lab Immunol 6:912–920PubMedPubMedCentral

Jenkins-Holick DS, Kaul TL (2013) Schistosomiasis. Urologic Nursing 33:163–170PubMed

Kallinikova VD et al (2006) Immunization against Trypanosoma cruzi and tumor growth in mice. Med Parazitologiia i parazitarnye bolezni 4:9–12

Kaplan MH, Whitfield JR, Boros DL (1950) Grusby MJ (1998) Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J Immunol 160:1850–1856

Karkut G (1984) Effect of lactobacillus immunotherapy on genital infections in women (Solco Trichovac/Gynatren)] [Abstract]. Geburtshilfe Frauenheilkd 44:311–314. doi:10.1055/s-2008-1036665 PubMedCrossRef

Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee YH (2007) Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 22(Suppl):S38–S46PubMedPubMedCentralCrossRef

Klaver EJ et al (2013) Trichuris suis-induced modulation of human dendritic cell function is glycan-mediated. Int J Parasitol 43:191–200. doi:10.1016/j.ijpara.2012.10.021 PubMedCrossRef

Kumar S, Tarleton RL (2001) Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol 166:4596–4603. doi:10.4049/jimmunol.166.7.4596 CrossRef

Liu MA (2003) DNA vaccines: a review. J Intern Med 253:402–410PubMedCrossRef

Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:62–84. doi:10.1111/j.1600-065X.2010.00980.x PubMedCrossRef

Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, Mayrink W (2002) Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 41:73–78PubMedCrossRef

Mayrink W, Magalhaes PA, Michalick MS, da Costa CA, Lima Ade O, Melo MN et al (1992) Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil [Abstract]. Parassitologia 34:159–165

Mayrink W, Botelho AC, Magalhaes PA, Batista SM, Lima Ade O, Genaro O et al (2006) Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 39:14–21PubMedCrossRef

Mel’nikov VG, Fierro Velasko FH, Dobrovinskaya OR (2004) Suppression of growth and metastasizing of T-cell lymphoma in mice infected with american trypanosomiasis at different stages of experimental infection. Bull Exp Biol Med 137:475–478PubMedCrossRef

Miyahara K et al (1992) Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats. J Vet Med Sci 54:221–228PubMedCrossRef

Nesterenko MV, Woods K, Upton SJ (1999) Receptor/ligand interactions between Cryptosporidium parvum and the surface of the host cell. Biochim Biophys Acta 1454:165–173PubMedCrossRef

Noguchi T, Ritter G, Nishikawa H (2013) Antibody-based therapy in colorectal cancer. Immunotherapy 5:533–545. doi:10.2217/imt.13.35 PubMedCrossRef

Oikonomopoulou K, Brinc D, Kyriacou K, Diamandis EP (2013) Infection and cancer: revaluation of the hygiene hypothesis. Clin Cancer Res 19:2834–2841. doi:10.1158/1078-0432.ccr-12-3661 PubMedCrossRef

Okwor I, Uzonna JE (2009) Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 1:765–776. doi:10.2217/imt.09.40 PubMedCrossRef

Oldham RK (1988) Principles of cancer biotherapy. Am J Clin Oncol 11:684CrossRef

Pavia CS (1986) Protection against experimental toxoplasmosis by adoptive immunotherapy. J Immunol 137:2985–2990PubMed

Perryman LE, Kapil SJ, Jones ML, Hunt EL (1999) Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein. Vaccine 17:2142–2149PubMedCrossRef

Petersen C, Gut J, Doyle PS, Crabb JH, Nelson RG, Leech JH (1992) Characterization of a >900,000-M(r) Cryptosporidium parvum sporozoite glycoprotein recognized by protective hyperimmune bovine colostral immunoglobulin. Infect Immun 60:5132–5138PubMedPubMedCentral

Pidherney MS, Alizadeh H, Stewart GL, McCulley JP, Niederkorn JY (1993) In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba. Cancer Lett 72:91–98PubMedCrossRef

Pritchard DI, Brown A (2001) Is Necator americanus approaching a mutualistic symbiotic relationship with humans? Trends Parasitol 17:169–172PubMedCrossRef

Rasouli S, Sadaghian M, Jafari R (2014) Prevalence of human toxoplasmosis and related risk factors using Electrochemiluminescence (ECLIA) method in West Azarbaijan Province, Iran, 2010. International J Biosci 4:124–130. doi:10.12692/ijb/4.8.124-130

Riggs M (1997) Immunology. In: Fayer R (ed) Cryptosporidium and Cryptosporidiosis, 1st edn. CRCPress, Boca Raton, pp 61–129

Riggs MW (2002) Recent advances in cryptosporidiosis: the immune response. Microbes Infect 4:1067–1080PubMedCrossRef

Riggs MW, Cama VA, Leary HL Jr, Sterling CR (1994) Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice. Infect Immun 62:1927–1939PubMedPubMedCentral

Riggs MW, McNeil MR, Perryman LE, Stone AL, Scherman MS, O’Connor RM (1999) Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a beta-mannosylated glycolipid. Infect Immun 67:1317–1322PubMedPubMedCentral

Rzepecka J, Harnett W (2013) Impact of worms and their products on eosinophils and neutrophils in experimental asthma. Curr Mol Med 13:1192–1202PubMedCrossRef

Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY (2013) High Prevalence of Multidrug Resistance and Metallo-beta-lactamase (MbetaL) producing Acinetobacter Baumannii Isolated from Patients in ICU Wards, Hamadan, Iran. J Res Health Sci 13:162–167PubMed

Safari M, Alikhani MY, Arabestani MR, Kamali Kakhki R, Jafari R (2014) Prevalence of Metallo-β-lactamases encoding genes among pseudomonas aeruginosa strains isolated from the bedridden patients in the intensive care units. Avicenna J Clin Microb Infec 1:e19216CrossRef

Santín M, Trout JM (2009) Livestock. In: Fayer R, Xiao L (eds) Cryptosporidium and cryptosporidiosis, 2nd edn. CRC Press/Taylor & Francis Group, New York, pp 451–483

Santos WR, Aguiar IA, de Paraguai Souza E, de Lima VM, Palatnik M, de Palatnik-Sousa CB (2003) Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21:4668–4676PubMedCrossRef

Schofield L, Vivas L, Hackett F, Gerold P, Schwarz RT, Tachado S (1993) Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of Plasmodium falciparum: prospects for the immunotherapy of severe malaria. Ann Trop Med Parasitol 87:617–626PubMed

Schwebke JR, Burgess D (2004) Trichomoniasis. Clin Microbiol Reviews 17:794–803. doi:10.1128/cmr.17.4.794-803.2004 CrossRef

Scrivener S, Yemaneberhan H, Zebenigus M, Tilahun D, Girma S, Ali S et al (2001) Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. Lancet 358:1493–1499. doi:10.1016/s0140-6736(01)06579-5

Shirzad H, Khorami S, Soozangar N, Yousefi M, Darani HY (2012) Toxoplasma gondii but Not Leishmania major or Trichomonas vaginalis decreases cell proliferation and increases cell death on fibrosarcoma cancer cells in culture medium world. J Vaccines 2:105–108

Spano F, Putignani L, Naitza S, Puri C, Wright S, Crisanti A (1998) Molecular cloning and expression analysis of a Cryptosporidium parvum gene encoding a new member of the thrombospondin family. Mol Biochem Parasitol 92:147–162PubMedCrossRef

Strong WB, Gut J, Nelson RG (2000) Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60 kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect Immun 68:4117–4134PubMedPubMedCentralCrossRef

Tarleton RL (2001) Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31:550–554PubMedCrossRef

Tarleton RL, Grusby MJ (1950) Zhang L (2000) Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol 165:1520–1525CrossRef

Taylor DW (1991) Monoclonal antibodies to a pan-malarial antigen. Google Patents

Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S (1998) Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 42:1959–1965PubMedPubMedCentral

Tosini F, Agnoli A, Mele R, Gomez Morales MA, Pozio E (2004) A new modular protein of Cryptosporidium parvum, with ricin B and LCCL domains, expressed in the sporozoite invasive stage. Mol Biochem Parasitol 134:137–147PubMedCrossRef

Tse BW, Collins A, Oehler MK, Zippelius A, Heinzelmann-Schwarz VA (2014) Antibody-based immunotherapy for ovarian cancer: where are we at? Ann Oncol 25:322–331. doi:10.1093/annonc/mdt405 PubMedCrossRef

Tzipori S, Rand W, Griffiths J, Widmer G, Crabb J (1994) Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin Diagn Lab Immunol 1:450–463PubMedPubMedCentral

van der Weiden RM, van der Meijden WI, Bogchelman DH, Polderman AM (1990) Treatment failure in trichomoniasis and persistence of the parasite after Lactobacillus immunotherapy; two case reports. Eur J Obstet Gynecol Reprod Biol 34:171–178PubMedCrossRef

Van Kaer L (2004) Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 82:315–322. doi:10.1111/j.0818-9641.2004.01252.x PubMedCrossRef

Verwaerde C, Thiam K, Delanoye A, Fernandez-Gomez R, D’Halluin J, Auriault C (1999) Systemic delivery of an adenovirus expressing EBV-derived vIL-10 in mice infected with Schistosoma mansoni or Leishmania amazonensis: controversial effects on the development of pathological parameters. Eur Cytokine Netw 10:161–170PubMed

Vineis P, Wild CP (2014) Global cancer patterns: causes and prevention. Lancet 383:549–557. doi:10.1016/s0140-6736(13)62224-2 PubMedCrossRef

Weiner LM, Murray JC, Shuptrine CW (2012) Antibody-based immunotherapy of cancer. Cell 148:1081–1084. doi:10.1016/j.cell.2012.02.034 PubMedPubMedCentralCrossRef

Wilson MT, Singh AK, Van Kaer L (2002) Immunotherapy with ligands of natural killer T cells. Trends Mol Med 8:225–231PubMedCrossRef

Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection [Abstract]. Nature 376:594–596. doi:10.1038/376594a0 PubMedCrossRef

Yazdanbakhsh M, Kremsner PG, van Ree R (2002) Allergy, parasites, and the hygiene hypothesis. Science 296:490–494PubMedCrossRef

Yousofi Darani H, Soozangar N, Khorami S, Taji F, Yousofi M, Shirzad H (2012) Hydatid Cyst Protoscolices Induce Cell Death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts in vitro. J Parasitol Res 2012:1–4. doi:10.1155/2012/304183 CrossRef

Zhou P, Chen Z, Li HL, Zheng H, He S, Lin RQ, Zhu XQ (2011) Toxoplasma gondii infection in humans in China. Parasites Vectors 4:165. doi:10.1186/1756-3305-4-165 PubMedPubMedCentralCrossRef

Title: Parasites and immunotherapy: with or against?
Authors: Hossein Yousofi Darani
Morteza Yousefi
Marzieh Safari
Rasool Jafari
Publication date: 01-06-2016
Publisher: Springer India
Published in: Journal of Parasitic Diseases / Issue 2/2016
Print ISSN: 0971-7196
Electronic ISSN: 0975-0703
DOI: https://doi.org/10.1007/s12639-014-0533-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Parasites and immunotherapy: with or against?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

In vitro and in vivo anthelmintic activity of Murraya koenigii against gastro-intestinal nematodes of sheep

Anticoccidial effects of herbal extracts on Eimeria tenella infection in broiler chickens: in vitro and in vivo study

Morphological characterization of Cysticercus cellulosae in naturally infected pigs in Punjab (India)

Serological study of Toxoplasma gondii infection in Turkoman horses in the North Khorasan Province, Iran

A report on the incidence of Trichodina heterodentata from fishes of Jammu, J&K India

Prevalence of ectoparasites in owned dogs in Kerman city, southeast of Iran

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page